David Chang is leaving his post as chief executive of Allogene Therapeutics, the company confirmed on Friday. The move ends his tenure at the helm of the publicly traded cell therapy developer, which has been working on off-the-shelf CAR-T treatments. Chang's departure comes as Allogene navigates a challenging market for experimental cancer therapies.
Allogene has faced setbacks in recent years, including a clinical hold from the FDA and mixed data from early-stage trials. The company's pipeline centers on allogeneic CAR-T cells, which are designed to be manufactured from donor cells rather than a patient's own immune system. That approach had drawn significant investor excitement before running into regulatory and scientific hurdles.
The company did not immediately name a permanent successor. Shares of Allogene have fallen more than 60% over the past 12 months, reflecting broader headwinds in the biotech sector. No financial terms of Chang's departure were disclosed.
Analysts are watching to see if the leadership shake-up signals a strategic pivot or potential acquisition. The cell therapy space remains intensely competitive, with approved products from Gilead and Bristol Myers Squibb already on the market. Any shift in Allogene's direction could ripple across the allogeneic CAR-T field.
The news comes amid a busy week for biotech, including Pfizer's multibillion-dollar push into Chinese drugs and WHO efforts to map an experimental response to the Ebola outbreak. However, these developments are not directly related to Allogene's CEO change.